Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kymera Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing oral small molecule degraders through targeted protein degradation. Its Form 8-K reports cover material events such as operating and financial results, clinical and regulatory disclosures, Regulation FD presentations, collaboration-related updates, and capital-raising arrangements involving common stock.
Proxy and governance filings describe shareholder voting matters, executive compensation, equity awards, board oversight, and bylaw provisions, including forum-selection language. The filing record also identifies KYMR common stock and recurring disclosure areas tied to the company’s pipeline, financing capacity, corporate governance, and public-company reporting obligations.
Noah Goodman reported insider sales of Common Stock via Rule 10b5-1 plans. The filing lists multiple dispositions between 04/09/2026 and 06/25/2026, including representative transactions of 5,764 shares for $500,582.20, 5,000 shares for $570,000.00, and other 10b5-1 sales. The report identifies the securities as Restricted Stock Units converted to Common and sold under pre-arranged plans.
Kymera Therapeutics director Bruce Booth reported indirect open-market sales of a total of 31,283 shares of Kymera common stock on June 29, 2026. The trades, executed at weighted-average prices between about $108 and $111 per share, were made under a pre-arranged Rule 10b5-1 trading plan by Atlas Venture funds that hold the shares, for which Booth disclaims beneficial ownership beyond any pecuniary interest.
Kymera Therapeutics, Inc. director Bruce Booth reported that investment entities associated with him, including Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., sold a combined 513,245 shares of Kymera common stock in open-market transactions.
The sales occurred on June 26 and June 29, 2026 at weighted-average prices such as $118.66 and $105.78 per share, executed under a pre-established Rule 10b5-1 trading plan. The filing shows that these entities continue to hold large indirect positions, including reported post-transaction holdings of 466,077 and 2,603,048 shares.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice to sell 61,378 shares of Common Stock tied to the exercise of stock options.
The filing also lists 15,731 Restricted Stock Units with an earlier grant date of 03/01/2025. The sales are presented on the form with an effective/filing date of 06/30/2026 and the securities are listed for trading on NASDAQ.
KYMR reported notices of proposed sale of Common Stock by multiple selling holders under Rule 144. The excerpt lists specific sale notices and recent transactions by holders such as Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., and individual holders including Bruce Booth.
The filings show proposed or recent sales on dates including 04/15/2026, 04/22/2026, and multiple dates in June 2026, with per‑transaction share counts and dollar amounts reported for each selling holder.
The issuer listed Common Stock for sale under Form 144 with Nasdaq listed securities; the notice is dated 06/29/2026. The excerpt lists multiple proposed sales by holders including Atlas Venture Funds and Bruce Booth with trade dates from 04/15/2026 through 06/26/2026.
Funds affiliated with BVF Partners reported significant stock sales in Kymera Therapeutics, Inc. common shares. On 2026-06-26, Section 13(d) group members filed a joint Form 4 showing open-market sales totaling 1,630,658 shares of Kymera common stock at $106.50 per share, split between direct and indirect holdings.
The filing also lists a series of vested and time-based stock options, with exercise prices ranging from $14.18 to $99.87 per share and expirations from 2030 to 2036, held indirectly through BVF-managed entities. In addition, the group retains several pre-funded warrants exercisable at $0.0001 per share that, according to the disclosure, are exercisable at any time and do not expire. Collectively, these derivatives indicate that BVF-affiliated vehicles remain substantial economic holders of Kymera beyond the reported common share sales.
Kymera Therapeutics’ large shareholder group BVF and related entities reported a significant secondary-market sale and updated their ownership. On June 26, 2026, BVF-affiliated funds and a managed account sold an aggregate 1,630,658 Kymera shares at $106.50 per share.
After these trades, BVF, BVF2, Biotechnology Value Trading Fund OS and the Partners Managed Account together beneficially own 5,237,151 shares, or approximately 6.3% of Kymera’s common stock, based on 82,257,588 shares outstanding as of April 24, 2026 plus shares underlying certain pre-funded warrants.
The group holds 1,365,099 pre-funded warrants with a de minimis $0.0001 exercise price that do not expire, subject to a 9.99% ownership cap and Hart-Scott-Rodino thresholds. Director Gorjan Hrustanovic’s board-related stock options, covering 116,190 shares vesting within 60 days, are subject to an agreement assigning their economic benefit to BVF Partners.
KYMR proposed a sale of 1,630,658 shares of Common Stock, recorded on 06/26/2026. The shares were acquired upon automatic conversion in connection with the issuer's IPO on 08/21/202003/11/2020
The filing lists $189,906,430.68 alongside the security line and indicates trading on NASDAQ. The filer name shown is Jefferies LLC at 520 Madison Ave, New York.
KYMR submitted a Form 144 notice disclosing proposed sales of Common Stock by several selling holders, including multiple sales by Atlas Venture Fund X, L.P. and affiliates between 04/15/2026 and 06/25/2026
The excerpt lists individual sale dates, share quantities, and gross proceeds for each transaction (for example, 480,992 shares for $57,122,898.52 on 06/25/2026). These are routine resale notices under applicable securities rules.